FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updat ...

Gilead Sciences Inc. (GILD) is set to report fourth-quarter 2023 results on Feb 6, after market close.The company has a mixed track record, with earnings beating estimates in two of the last four quarters and missing in the remaining two, the average negative surprise being 0.24%. In the last reported quarter, the company posted an earnings surprise of 19.9%.Factors to NoteRevenues in the fourth quarter have likely been boosted by growth in oncology and HIV franchise sales. However, a decline in Veklury (re ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global c ...

Analysts on Wall Street project that Gilead Sciences (GILD) will announce quarterly earnings of $1.76 per share in its forthcoming report, representing an increase of 5.4% year over year. Revenues are projected to reach $7.08 billion, declining 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estim ...

Gilead Sciences (GILD) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 6, 2024, might help the stock move higher if these key numbers are better ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manufactu ...

Gilead Sciences (GILD) closed at $79.07 in the latest trading session, marking a -0.57% move from the prior day. This change lagged the S&P 500's daily gain of 0.76%. Meanwhile, the Dow gained 0.59%, and the Nasdaq, a tech-heavy index, added 1.12%.The HIV and hepatitis C drugmaker's shares have seen a decrease of 1.84% over the last month, not keeping up with the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.Analysts and investors alike will be keeping a close eye on the performance of Gilea ...

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gi ...

The latest trading session saw Gilead Sciences (GILD) ending at $79.48, denoting a +1.34% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.29%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq gained 0.43%.The HIV and hepatitis C drugmaker's shares have seen a decrease of 1.54% over the last month, not keeping up with the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.The investment community will be paying close attentio ...